FBL-145

FBL-145 is a multifunctional incretin conjugate currently in the discovery phase, developed by Fable Therapeutics for the treatment of obesity and cardiometabolic diseases. The drug is designed to simultaneously target the incretin pathway (typically involving GLP-1 and/or GIP receptors) and the activin receptor type 2A and 2B (ActR2A/B). By combining incretin agonism with activin receptor antagonism, FBL-145 aims to achieve significant weight reduction while potentially mitigating the loss of lean muscle mass, a common side effect of potent weight-loss therapies. This dual-action approach leverages the metabolic benefits of incretins alongside the muscle-preserving effects of inhibiting the myostatin/activin signaling pathway.